文献速递白血病淋巴瘤

儿童B细胞急性淋巴细胞白血病复发中的获得性硫嘌呤耐药与错配修复异常:整合突变特征、克隆与临床硫嘌呤剂量模式的真实世界数据

Acquired thiopurine resistance and mismatch repair aberrations in paediatric B-cell acute lymphoblastic leukaemia relapse: A real-world data integrating mutational signatures, clones and clinical thiopurine dosing patterns.
PubMed 文献 · Br J Haematol · 2026-05-26

该真实世界研究对75例儿童B-ALL复发样本行全外显子组或深度靶向测序,分析硫嘌呤耐药基因突变、突变特征及MMR基因克隆。18/75(24%)复发样本携带SBS87、SBS6/15或Thio-dMMR突变特征,19/75(25%)存在NT5C2、PRPS1或TP53耐药克隆,19/75(25%)存在MMR基因胚系或体细胞克隆。低中位周6-MP剂量(<45 mg/m2)和≥4周剂量中断均与SBS87或Thio-dMMR特征风险升高显著相关。

要点

  • 复发时24%样本携带硫嘌呤相关或MMR相关突变特征,25%存在硫嘌呤耐药克隆。
  • 低中位周6-MP剂量(<45 mg/m2)与硫嘌呤耐药/MMR特征风险升高相关(HR 7.09)。
  • ≥4周6-MP剂量中断与硫嘌呤耐药/MMR特征风险升高相关(HR 6.21)。

核心结论

  • 维持治疗期间次优的中位6-MP剂量和 prolonged 剂量中断与复发时硫嘌呤耐药及MMR缺陷相关突变特征显著相关。

研究设计与样本

  • 真实世界研究,纳入2018-2024年儿童B-ALL复发病例,全外显子组测序(200-250×深度;n=70)和深度靶向测序(700-900×;n=5),共75例。

主要发现

  • 18/75(24%)复发样本显示SBS87(硫嘌呤相关)、SBS6/15(MMR相关)或Thio-dMMR突变特征。
  • 19/75(25%)病例检出NT5C2(13)、PRPS1(2)或TP53(7)硫嘌呤耐药克隆;19/75(25%)病例检出MMR基因胚系或体细胞克隆。
  • 低中位周6-MP剂量(<45 mg/m2)与SBS87或Thio-dMMR特征风险升高相关(HR 7.09,95%CI 1.77-28.34,p=0.006)。
  • ≥4周6-MP剂量中断与SBS87或Thio-dMMR特征风险升高相关(HR 6.21,95%CI 1.66-23.32,p=0.007)。

关键数值与推荐

  • 硫嘌呤耐药相关突变特征包括SBS87、SBS6/15和Thio-dMMR。
  • 低中位周6-MP剂量定义为<45 mg/m2(时间加权)。
  • 剂量中断定义为≥4周。

临床怎么用

  • 儿童B-ALL维持治疗中应优化6-MP剂量强度并尽量减少不必要的剂量中断,以降低硫嘌呤耐药和MMR缺陷相关复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acquired thiopurine resistance and mismatch repair (MMR) deficiency are increasingly recognised drivers of relapse in paediatric B-cell acute lymphoblastic leukaemia (B-ALL); however, their real-world genomic prevalence and link to maintenance dosing patterns remain poorly characterised. Paediatric B-ALL relapse cases (2018-2024) were subjected to whole exome sequencing (WES; 200-250× depth; n = 70) and deep targeted sequencing (700-900×; n = 5). Per-sample frequencies of resistance gene mutations, single-base mutational signatures, tumour mutational burden-high (≥10 mutations/Mb), microsatellite instability-high (MSI-H) and thiopurine S-methyltransferase (TPMT)/nucleoside diphosphate-linked moiety X-type motif 15 (NUDT15) status were determined. Clinical variables included the median weekly 6-mercaptopurine (6-MP) dose (mg/m2, time-weighted) and duration of 6-MP dose interruptions. A total of 18/75 (24%) relapse cases showed SBS87 (thiopurine-related), SBS6/15 (MMR-related) or Thio-deficient mismatch repair (Thio-dMMR) mutational signature. Thiopurine resistance clones in cytosolic 5'-nucleotidase II (NT5C2) (13), phosphoribosyl pyrophosphate synthetase 1 (PRPS1) (2) or tumor protein p53 (TP53) (7) were noted in 19/75 (25%) cases; germline or somatic clones in MMR genes were noted in 19/75 (25%). Correlation analysis revealed that both low median weekly 6-MP dose (<45 mg/m2) and ≥4 weeks of dose interruptions were significantly associated with higher hazard for SBS87 or Thio-dMMR signature (hazard ratio [HR] 7.09 [95% confidence interval (CI): 1.77-28.34], p = 0.006, and HR 6.21 [95% CI: 1.66-23.32], p = 0.007 respectively). This real-world study demonstrates that suboptimal median 6-MP dosing and prolonged dose interruptions during maintenance are significantly associated with thiopurine resistance and MMR deficiency-related mutational signatures at relapse. These findings underscore the importance of optimised dose intensity and minimal interruptions during maintenance therapy in paediatric B-ALL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Bhatia P, Sharun S, Palla S, et al. Acquired thiopurine resistance and mismatch repair aberrations in paediatric B-cell acute lymphoblastic leukaemia relapse: A real-world data integrating mutational signatures, clones and clinical thiopurine dosing patterns. Br J Haematol. 2026. PMID: 42189079. doi:10.1111/bjh.70560

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。